|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 17, 2017 ) Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 19, 1, 44, 5 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 7, 6, 13 and 3 molecules, respectively.
Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
For more information about this report at http://www.reportsweb.com/neuroblastoma-pipeline-review-h1-2017
Report Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology) .
- The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001834377/sample
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles
Ability Pharmaceuticals SL
Actuate Therapeutics Inc
Advanced Accelerator Applications SA
Alissa Pharma
Ampio Pharmaceuticals Inc
APAvadis Biotechnologies Srl
APEIRON Biologics AG
AstraZeneca Plc
Bayer AG
Bellicum Pharmaceuticals Inc
Bexion Pharmaceuticals LLC
BioLineRx Ltd
Biotec Pharmacon ASA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cancer Prevention Pharmaceuticals Inc
Cebiotex SL
Celgene Corp
Celldex Therapeutics Inc
Cielo Therapeutics Inc
Cleveland BioLabs Inc
CorMedix Inc
Curis Inc
Cyclacel Pharmaceuticals Inc
DEKK-TEC Inc
EnGeneIC Ltd
Errant Gene Therapeutics LLC
F. Hoffmann-La Roche Ltd
GlaxoSmithKline Plc
Green Cross Cell Corp
Ignyta Inc
Juno Therapeutics Inc
Lindis Biotech GmbH
MabVax Therapeutics Holdings Inc
MacroGenics Inc
MediaPharma srl
Merck & Co Inc
Merrimack Pharmaceuticals Inc
Morphogenesis Inc
Novartis AG
Novogen Ltd
OGD2 Pharma SAS
Pfizer Inc
Phylogica Ltd
Progenics Pharmaceuticals Inc
Recombio SL
Ribomic Inc
Sapience Therapeutics Inc
Sareum Holdings Plc
Shionogi & Co Ltd
Sierra Oncology Inc
Syros Pharmaceuticals Inc
Tiltan Pharma Ltd
Trovagene Inc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001834377/discount
List of Tables
Number of Products under Development for Neuroblastoma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
Products under Development by Companies, H1 2017 (Contd..3) , H1 2017
Products under Development by Companies, H1 2017 (Contd..4) , H1 2017
Products under Development by Universities/Institutes, H1 2017
Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H1 2017
Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H1 2017
Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H1 2017
Neuroblastoma - Pipeline by Alissa Pharma, H1 2017
Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
Neuroblastoma - Pipeline by APAvadis Biotechnologies Srl, H1 2017
Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2017
Neuroblastoma - Pipeline by AstraZeneca Plc, H1 2017
Neuroblastoma - Pipeline by Bayer AG, H1 2017
Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
Neuroblastoma - Pipeline by BioLineRx Ltd, H1 2017
Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H1 2017
Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
Neuroblastoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
Neuroblastoma - Pipeline by Cebiotex SL, H1 2017
Neuroblastoma - Pipeline by Celgene Corp, H1 2017
Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H1 2017
Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H1 2017
Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H1 2017
Neuroblastoma - Pipeline by CorMedix Inc, H1 2017
Neuroblastoma - Pipeline by Curis Inc, H1 2017
Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
Neuroblastoma - Pipeline by DEKK-TEC Inc, H1 2017
Neuroblastoma - Pipeline by EnGeneIC Ltd, H1 2017
Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H1 2017
Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H1 2017
Neuroblastoma - Pipeline by Green Cross Cell Corp, H1 2017
Neuroblastoma - Pipeline by Ignyta Inc, H1 2017
Neuroblastoma - Pipeline by Juno Therapeutics Inc, H1 2017
Neuroblastoma - Pipeline by Lindis Biotech GmbH, H1 2017
Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
Neuroblastoma - Pipeline by MacroGenics Inc, H1 2017
Neuroblastoma - Pipeline by MediaPharma srl, H1 2017
Neuroblastoma - Pipeline by Merck & Co Inc, H1 2017
Neuroblastoma - Pipeline by Merrimack Pharmaceuticals Inc, H1 2017
Neuroblastoma - Pipeline by Morphogenesis Inc, H1 2017
Neuroblastoma - Pipeline by Novartis AG, H1 2017
Neuroblastoma - Pipeline by Novogen Ltd, H1 2017
Neuroblastoma - Pipeline by OGD2 Pharma SAS, H1 2017
Neuroblastoma - Pipeline by Pfizer Inc, H1 2017
Neuroblastoma - Pipeline by Phylogica Ltd, H1 2017
Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H1 2017
Neuroblastoma - Pipeline by Recombio SL, H1 2017
Neuroblastoma - Pipeline by Ribomic Inc, H1 2017
Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H1 2017
Neuroblastoma - Pipeline by Sareum Holdings Plc, H1 2017
Neuroblastoma - Pipeline by Shionogi & Co Ltd, H1 2017
Neuroblastoma - Pipeline by Sierra Oncology Inc, H1 2017
Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H1 2017
Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H1 2017
Neuroblastoma - Pipeline by Trovagene Inc, H1 2017
Neuroblastoma - Dormant Projects, H1 2017
Neuroblastoma - Dormant Projects, H1 2017 (Contd..1) , H1 2017
Neuroblastoma - Dormant Projects, H1 2017 (Contd..2) , H1 2017
Neuroblastoma - Discontinued Products, H1 2017
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001834377/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
